Literature DB >> 29269429

Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"

Charles A Peloquin1, Russell R Kempker2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29269429      PMCID： PMC5740389          DOI： 10.1128/AAC.01937-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

Review 1.  The Role of Therapeutic Drug Monitoring in Mycobacterial Infections.

Authors:  Charles Peloquin
Journal:  Microbiol Spectr       Date:  2017-01

2.  Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.

Authors:  Molly F Franke; Mercedes C Becerra; Dylan B Tierney; Michael L Rich; Cesar Bonilla; Jaime Bayona; Megan M McLaughlin; Carole D Mitnick
Journal:  Ann Am Thorac Soc       Date:  2015-05

3.  Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 4.  Optimizing the clinical pharmacology of tuberculosis medications.

Authors:  E F Egelund; A Alsultan; C A Peloquin
Journal:  Clin Pharmacol Ther       Date:  2015-07-22       Impact factor: 6.875

5.  A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

Authors:  Martin J Boeree; Andreas H Diacon; Rodney Dawson; Kim Narunsky; Jeannine du Bois; Amour Venter; Patrick P J Phillips; Stephen H Gillespie; Timothy D McHugh; Michael Hoelscher; Norbert Heinrich; Sunita Rehal; Dick van Soolingen; Jakko van Ingen; Cecile Magis-Escurra; David Burger; Georgette Plemper van Balen; Rob E Aarnoutse
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 21.405

6.  Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Authors:  Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

7.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

8.  Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.

Authors:  Deepak V Almeida; Sandeep Tyagi; Si-Yang Li; Kristina Wallengren; Alexander S Pym; Nicole C Ammerman; William R Bishai; Jacques H Grosset
Journal:  Mycobact Dis       Date:  2014-05-05

9.  Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Authors:  R M Savic; M Weiner; W R MacKenzie; M Engle; W C Whitworth; J L Johnson; P Nsubuga; P Nahid; N V Nguyen; C A Peloquin; K E Dooley; S E Dorman
Journal:  Clin Pharmacol Ther       Date:  2017-03-02       Impact factor: 6.875
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.